Introduction
Alopecia areata (AA) is an autoimmune hair loss disorder with variable clinical presentations ranging from patchy to complete loss of scalp and body hair. The pathogenesis involves the collapse of hair follicle immune privilege, allowing infiltration by autoreactive CD8+ cytotoxic T cells that initiate inflammation. These T cells secrete interferon-gamma (IFN-γ), which upregulates IL-15 expression on follicular epithelial cells. IL-15 then acts on nearby T cells to create a pathogenic feedback loop that further amplifies T cell-mediated inflammation and IFN-γ production. Furthermore, IFN-γ signals through the JAK-STAT pathway to stimulate macrophage recruitment and upregulate MHC class I molecules on follicular cells. This loss of immune privilege exposes hair follicles to CD8+ NKG2D+ T cells, facilitating autoimmune damage. Additionally, CD4+ T cells have been identified within perifollicular infiltrates, implicating a broader T cell immune response that may contribute to systemic AA.1 The recent therapeutic evolution in AA reflects a broader shift toward precision immunomodulation with the FDA approval of three oral JAK inhibitors: baricitinib, ritlecitinib, and deuruxolitinib. This commentary highlights key clinical trials and emerging therapies that dermatologists should be following to stay informed and better guide their patients.
JAK Inhibitors
Upadacitinib, a JAK1-selective inhibitor, is currently being evaluated in an active phase 3 trial. Retrospective studies have demonstrated its potential efficacy, with one study reporting that 88% of 17 patients achieved SALT50, and another showing complete or partial regrowth in 100% of a 22-patient corhort, with 63.6% achieving complete scalp hair regrowth.2,3 Similarly, ivarmacitinib, another JAK1 selective inhibitor, demonstrated clinical benefit in a phase II trial, where patients treated for 24 weeks achieved mean SALT score reductions of 56.1% and 51.0%, compared to 19.9% in the placebo group.4 It is also currently in an active phase 3 trial. Additional JAK inhibitors in trials include Jaktinib (JAK1/JAK2/JAK3/TYK2) and SYHX1901 (JAK1/JAK2/TYK2 inhibitor). JAK-STAT signaling is highly prominent in AA pathogenesis. Cytokines activate CD8+ T cells through JAK1 and JAK3, which promotes the proliferation and production of IFN-γ. IFN-γ then signals through the JAK1/JAK2-STAT1 axis to increase IL-15 activity. In addition, other proinflammatory cytokines, such as IL-12 and IL-23, signal through via JAK2-STAT3 and TYK2-STAT4 which contributes to cytokine secretion by Th17 cells.1 These pathways sustain chronic inflammation and autoreactive T cell activity around the hair follicle.
Interleukin Modulators
Beyond JAK inhibition, IL-4/IL-13 blockade with dupilumab has generated results with SALT75 responses in up to 38.5% of patients with elevated baseline IgE. These findings support a role for Th2-driven inflammation, as IL-4 and IL-13 are key Th2 cytokines involved in IgE stimulation and allergic-type immune responses. The observation that dupilumab responders had higher IgE levels suggests that Th2-skewed immune activation may underlie disease in a subset of AA patients.5 Another agent that affects T cells is ADX-914, an anti-IL-7Rα antibody, which is currently in a recruiting and an active phase 2 trial. Upregulation of IL-7 and its receptor (IL-7Rα) has been observed in lesional scalp tissue from both humans and C3H/HeJ mice. IL-7 signaling promotes the expansion and survival of IFN-y producing cytotoxic T cells. In preclinical models, blockade of IL-7Rα prevented disease progression and reversed early-stage AA.6
Treg Modulation and OX40 Axis Blockade
Regulatory T cell (Treg) dysfunction has also been implicated in AA, with impaired suppression of effector T cells contributing to immune dysregulation.1 Rezpegaldesleukin is an IL-2R agonist and is currently in a phase 2 trial. It aims to restore the balance of Treg dysfunction by promoting Treg proliferation and activation.
Another emerging target is the OX40-OX40L costimulatory axis, which supports sustained T-cell activation. OX40, expressed on activated CD4+ and CD8+ T cells, binds to OX40L, found on dendritic cells, B cells, and mast cells. This interaction promotes T cell proliferation and amplifies Th1 and Th2 responses. Upregulation of OX40-OX40L signaling has been observed in AA lesional scalp tissue. IMG-007, an anti-OX40 monoclonal antibody, and amlitelimab, an anti-OX40L antibody, are both in active phase 2 trials. By blocking this interaction, these agents may reduce effector T-cell driven follicula.7 OX40 signaling occurs






